Island Secures USAMRIID Support for Galidesivir Study
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Island Pharmaceuticals Ltd has announced the execution of an expanded Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases for a Galidesivir study. The agreement confirms the planned dose optimisation study, which aims to identify the minimally effective dose of Galidesivir against the Angola strain of Marburg. The study is expected to commence soon, with topline results anticipated later in the year. This development represents a significant milestone for Island, enhancing its operational readiness for future studies and regulatory approvals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Island Pharmaceuticals Ltd on 6ix
In the deck
Story so far
Earlier from Island Pharmaceuticals
- Island Advances Galidesivir GMP Manufacturing for Biodefence
- Island Adds Biodefence Leader as Filovirus Risks Escalate
- Island Bolsters US Biodefence Readiness Ahead of Trials
- Antiviral pipeline expansion through strategic collaboration
- US Government collaboration for Galidesivir development
Later from Island Pharmaceuticals
- Investor presentation
- Investor Presentation - Asia Dengue Summit
- FDA Grants Orphan Designation for Galidesivir in Marburg
- Singapore Patent Expands Island's ISLA 101 Viral Protection
- Pause in Trading
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals